Abstract Despite contributing significantly to the burden of global disease, the translation of new treatment strategies for diseases of the central nervous system (CNS) from animals to humans remains challenging, with a high attrition rate in the development of CNS drugs. The failure of clinical trials for CNS therapies can be partially explained by factors related to pharmacokinetics/pharmacodynamics (PK/PD), such as lack of efficacy or improper selection of the initial dosage. A focused assessment is needed for CNS-acting drugs in first-in-human studies to identify the differences in PK/PD from animal models, as well as to choose the appropriate dose. In this review, we summarize the available literature from human studies on the PK and PD in brain tissue, cerebrospinal fluid, and interstitial fluid for drugs used in the treatment of psychosis, Alzheimer's disease and neuro-HIV, and address critical questions in the field. We also explore newer methods to characterize PK/PD relationships that may lead to more efficient dose selection in CNS drug development.
Introduction
Disorders of the brain contribute significantly to global disease burden. Psychiatric, neurological, developmental, and substance abuse disorders affect more than 1 billion people worldwide [1] . As of 2010, these were the leading causes of years lived with disability (YLD) globally, accounting for approximately 30% of all YLDs [2] . However, central nervous system (CNS) drug development is extremely challenging. Compared with non-CNS drug development, these programs have a lower clinical approval rate (6 vs. 13%) and a longer time to market (12 vs. 6-7 years) [3] [4] [5] [6] . This has led to several companies withdrawing drug development programs in the neurosciences [7] [8] [9] , signaling an uncertain future for novel research in CNS disorders.
Difficulty selecting initial drug dosage, untoward toxicities, and lack of efficacy are cited as some driving forces Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40262-018-0632-y) contains supplementary material, which is available to authorized users.
behind the high attrition rate of CNS therapies [10] . A robust concentration-effect analysis can provide valuable, reproducible information regarding both the therapeutic and adverse effect drug profile over a wide range of doses, and greatly aid the development of CNS-acting drugs. However, a report from 2007 indicated that very few sets of pharmacodynamic (PD) data were generated from human studies over a wide range of doses or concentrations [11] . Although concentration-effect relationships are assessed in animals, animal models do not always accurately predict human disease, especially in the case of CNS disorders [12] . The difference in blood-brain barrier (BBB) permeability, drug metabolizing enzymes and transporters can lead to differences in drug exposure in the human brain compared with animals [13] , and only rarely can drug be sampled from the human brain for pharmacokinetic (PK) measures. Furthermore, animal models may only mimic some mechanisms of human CNS disease or contain targets not seen in humans, challenging the translation of efficacy and/or toxicity of novel therapeutics. Therefore, to address these issues, a focused (PK/PD assessment is required in humans to identify differences from animal models and to adjust dosing. This has been accomplished by employing alternate methodologies such as in vitro systems, translational studies, or in silico modeling to supplement the understanding of pharmacology within the CNS.
This review is broadly divided into three parts. In Sect. 3, existing methods to measure PK and PD in the brain tissue, cerebrospinal fluid (CSF), and interstitial fluid (ISF) are reviewed. While there is abundance of PK/PD information from animal models in the CNS, less complete information is available from human studies. In Sects. 4-6, we examine clinical PK/PD analyses at relevant target sites in the CNS for antipsychotics, anti-Alzheimer's drugs, and antiretrovirals (ARVs), and examine the utility of available information and the need for more research to answer critical questions in the field. In the absence of clinical results, available animal data are presented and cautiously interpreted for clinical relevance. Finally, new methods to improve CNS drug development are examined in Sect. 7.
Methodology
An extensive literature search was performed to identify research articles and conference abstracts published in EMBASE (including articles in the MEDLINE Ò database) using terms for drugs used to treat disorders of the brain and CNS, combined with terms for PK or PD and terms for the brain and CNS. A full search strategy is provided in the electronic supplementary material. These searches were augmented by targeted searches in the PubMed, Google Scholar, and Google Books databases, which combined terms from the full search strategy plus additional terms for PK or PD measures or factors affecting these measures. The bibliographies of relevant review articles were also hand searched for additional relevant studies.
3 Pharmacokinetic (PK) and Pharmacodynamic (PD) Considerations for Drugs Acting in the Central Nervous System (CNS)
Measures of Drug PK in the CNS
Drug distribution into the CNS has been characterized by several methods, i.e. measuring drug uptake into cultured brain cells (in vitro), or measuring drug concentration in the brain tissue (ex vivo) or CSF or ISF (in vivo).
In vitro models of the BBB are used as a first-line approach for determining the extent to which investigational agents cross into the brain [14] . There are several validated models of the BBB from multiple species [15] and while no ideal cell line exists, the human cell line most widely used and well-characterized is the human immortalized endothelial cell line hCMEC/D3. hCMEC/D3 experiments can quantify drug permeability, identify relevant drug efflux transporter interactions, rapidly screen drug candidates for CNS activity, and carry out initial PK studies; however, these models are a static measure of drug PK. For anti-infectives in particular, these models do not account for time-dependent killing and may be less clinically relevant. In vitro systems also do not fully replicate all in vivo features of the BBB. For example, hCMEC/D3 is more 'leaky' than the BBB and can express lower levels of BBB-specific enzymes and drug transporters [15] . Therefore, in vitro systems may have to undergo modification such as co-culture with other brain cells to replicate tight junctions of the BBB [16] . Newer microfluidic technologies such as BBB-on-a-chip or neurovascular unit-ona-chip [17] hold promise to mimic the dynamic in vivo environment.
There are several ex vivo approaches for measuring drug concentrations in brain tissue, either after surgical resection or necropsy. Most PK information comes from brain tissue homogenates using liquid chromatography-mass spectrometry (LC-MS) analysis. These measurements are then used to calculate ISF and intracellular fluid (ICF) concentrations [18] . Although commonly used, these methods do not provide information about drug localization. Mass spectrometry (MS) imaging has emerged as a method to quantify drug molecules by MS and spatially visualize drug distribution in tissue slices [19] . The advantage of MS imaging is that it can capture drug distribution patterns within different regions of a tissue [20] . For example, using matrix-assisted laser desorption ionization (MALDI) MS imaging, the antitubercular drug pretomanid was found to localize predominantly in the corpus callosum of Sprague-Dawley rats [21] . By using serial sections collected at different time points, it was shown that pretomanid distributed into the corpus callosum 1-2 h after an intraperitoneal dose of 20 mg/kg, and diffused into other parts of the brain at later time points. With advances in imaging technology, this technique may be used to image intracellular drug concentrations and can be coupled with PD targets through immunohistochemistry (IHC) or in situ hybridization in contiguous slices. While this has not yet been demonstrated for brain cells, Aikawa et al. used hematoxylin and eosin (H&E) staining, along with IHC staining, for CD31 and multidrug resistance transporter 1 (MDR1) to show the co-localization of the anticancer drug alectinib with blood vessels in murine brains [22] . A drawback of ex vivo imaging is that it is a static measurement and a composite of multiple images from different animals is required to gain information across a dosing interval.
In vivo imaging techniques, such as positron emission tomography (PET), can provide longitudinal information on drug disposition. PET is a non-invasive imaging technique that relies on the detection of radiolabeled ligands over time. It has been used to measure absolute spatial concentration of drug and determine PK parameters, as well as target occupancy of several CNS-acting drugs. While a detailed discussion of PET is beyond the scope of this review, the reader is directed to a 2013 review [23] for a detailed summary on estimating PK parameters using PET studies. Despite the spatial advantages and applicability to human studies, PET scans are expensive, generally limited to fewer patients because of the use of radioactivity, and may not distinguish between parent compound and metabolites.
Other in vivo drug estimation methods measure drug penetration into fluid compartments of the CNS. Microdialysis involves inserting a dialysis probe into the cerebral region of the brain to measure the protein-unbound concentration in the ISF. This technique is regularly used in animal models for continuous monitoring of drug concentration but is only applicable during intraoperative procedures in humans [24] . Furthermore, this procedure might not be suitable for measuring the concentration of highly lipophilic or protein-bound drugs as there can be a high degree of non-specific binding to the microdialysis probe and poor recovery of drug from the fluid [24, 25] . Additionally, intracellular active metabolites are not captured using this technique.
The most common approach to generating PK data is drug sampling in CSF. This is done by lumbar puncture for a single sample and spinal catheterization in the subarachnoidal space for continuous sampling. While less invasive than microdialysis, lumbar punctures are painful and not without medical risks, and are not routinely performed. In addition, concentrations measured by lumbar puncture can differ based on the location and time of measurement [13] . For example, using a mathematical model, phenytoin was predicted to reach 300% greater concentration in cranial CSF than spinal CSF [26] . Generally, unbound CSF concentrations are used as surrogates for unbound brain tissue concentrations in animal models [27] based on the 'free drug hypothesis', which stipulates that protein-unbound drug passively moves from the plasma through the BBB and blood-CSF barrier (BCSFB) into the brain and CSF [28] . However, this generalization holds true for certain drugs [29, 30] , with two significant exceptions: (i) drugs that use membrane transporters for influx and efflux (e.g. antidepressants, ARVs); and (ii) drugs with low permeability to cross through the BBB where CSF bulk flow exceeds passive diffusion of the compound into CSF [31] . For substrates of efflux membrane transporters such as P-glycoprotein (P-gp), CSF concentrations tend to overestimate ISF concentrations [32] . While the exact reason for this observation remains unknown, some hypotheses include subapical or apical localization of P-gp on the choroid plexus that results in drug transfer and accumulation into the CSF [33] , or nonfunctionality of P-gp at the BCSFB [34] . Since the CSF is recycled at a faster rate than ISF, the CSF acts as a 'sink' to clear drug [31] . For high permeability compounds, this effect is negligible, but for low-permeability compounds, CSF concentrations underestimate the brain or ISF concentrations (e.g. morphine-6-glucuronide). Therefore, the unbound concentration in the brain may differ from the CSF concentration and confound target site assumptions.
In case of in vivo measurements made at a single time point, the concentration of drug in brain or CSF may be normalized to a simultaneously collected plasma concentration. While this is a common means of estimating the extent of drug uptake into the CNS, and allows for comparisons of uptake between drugs, the rates of entry and elimination of the drug in plasma, CSF, and brain compartments differ [35] . For example, the CSF:plasma concentration ratio for ciprofloxacin increases by as much as 1400% over 24 h [35] . One approach to avoid this confounding is to use sparse serial sampling in a group of animals or humans to characterize the drug's full PK profile in the CSF and plasma, and calculate the ratio of drug exposure in the two compartments by measuring the area under the concentration-time curve. This approach has been performed for several anti-infective drugs [36] during ventricle catheterization when CNS infections need to be monitored [37] or excess CSF fluid needs to be drained [38, 39] . Due to difficulties in obtaining multiple CSF samples from patients, population PK modeling has been used with sparse CSF and plasma sampling in order to obtain exposure profiles of various drugs such as abacavir [40] .
Intracellular versus Extracellular Drug Concentrations
When considering the site of action, it is important to distinguish between extracellular and intracellular CNS drug concentrations. For drugs that act on receptors on neuronal cell membranes such as antiepileptic drugs (AEDs) and anti-Alzheimer's drugs, it is preferable to measure drug concentration in the ISF where the PD effect is exerted. Extracellular-acting drugs have been measured in brain tissue homogenates, but this approach may be misleading. For AEDs and other basic drugs (pKa [7) where brain volume of distribution is greater than brain water volume (0.8 mL/g), ISF concentrations are overestimated by brain tissue homogenate due to non-specific binding in brain tissue [41, 42] . For anti-infective and anticancer drugs that act on intracellular targets, the unbound intracellular drug concentration is the most appropriate PK measure linked with activity. Fridén and colleagues demonstrated a method to indirectly estimate unbound intracellular drug concentration. Briefly, in vitro volume of distribution of unbound drug in brain (V u,brain ) is measured in brain slices from drug-naive animals incubated in drug containing buffer (brain slice method [43] ), and fraction of unbound drug in the brain (f u,brain ) is measured by adding drug to brain homogenates from drugnaive animals [18] . The ratio of intracellular to extracellular unbound drug concentration (K p,uu,cell ) is shown in Eq. 1.
Using this method, intracellular drug concentrations of gabapentin, oxycodone, morphine, and codeine were found to be greater than extracellular concentrations [18] .
Factors Affecting the PK of Drugs in the CNS
Many factors have been identified to affect drug exposure in the CNS. These have been summarized in Fig. 1 . For an in-depth analysis on specific classes of drugs, the reader is referred to two excellent reviews [36, 44] . [31] . These proteins can also be synthesized by microglial cells [45] . Therefore, while highly protein-bound drugs ([95% protein binding) such as efavirenz and fluoxetine have lower total drug concentrations in the CSF compared with blood plasma, protein-unbound drug concentrations are similar in both fluids. In general, the use of unbound drug concentrations in the CSF leads to mechanistic PK/PD relationships [46] and better translatability between species [47] . (b) Drug Efflux Transporters Drug efflux transporters such as MDR1 (P-gp), BCRP, and multidrug resistance protein 4 (MRP4) are highly expressed at the BBB [48] [49] [50] . MDR1 and MRPs have also been identified on the surface of astrocytes [48] . Studies using transporter knockout (KO) mice have shown that MDR1 KO increases brain concentrations of MDR1 substrates by 10-to 100-fold [51] , while the KO of BCRP and MRP4 has minimal effect [52, 53] . Therefore, MDR1 inhibition should be a viable option for increasing the CNS exposure of drugs in rodent models. Indeed, it has been shown that the coadministration of MDR1 inhibitors (e.g. cyclosporin or zosuquidar) increases CNS brain penetration of MDR1 substrates such as nelfinavir or paclitaxel [54] . For indinavir [55] , increased CSF penetration was demonstrated in HIV-infected patients when the MDR1 inhibitor ritonavir was administered concomitantly. Although there was an increase in plasma exposure, this was driven by a fivefold increase in trough concentration. Linear regression analysis showed that the increase in CSF concentrations (2.67-fold) was not explained by the increase in plasma concentrations alone, and inhibition of efflux transporters at the BBB might also contribute to increased CSF exposure of indinavir. (c) Physicochemical properties Lipophilic drugs show greater permeability through the lipophilic BBB. In a study of compounds ranging from highly polar (sucrose, logD = -4.49) to highly lipophilic (estradiol, logD = 4.14), the log brain uptake index (BUI) of estradiol in Sprague-Dawley rats was 232 times higher than sucrose [56] ; however, a higher lipophilicity also results in a higher degree of nonspecific tissue binding [57] . In a study of seven compounds that ranged in BBB permeability by 160-fold, the highly lipophilic compound fluoxetine showed the greatest permeability through the BBB (evidenced by the highest permeability surface area product of 600 mL/kg*h) of Sprague-Dawley rats but a free drug fraction (0.23%) [58] that was lower than plasma (6-15%). Similarly, efavirenz has a permeability surface area product of 2.4 mL/kg*h through the BBB, and a free fraction of only 0.197% [59] in rat brain tissue, compared with 1% in blood plasma.
Measures of Drug PD in the CNS
Many PD targets are utilized in CNS disorders. In the following section, common clinical PD endpoints are summarized. The pros and cons of these measures are outlined in Table 1 . .08 lM, respectively [60] . The drugs showed higher affinity to the phencyclidine (PCP) binding site on the receptor (10.5 ± 6.1 lM for amantadine and 0.54 ± 0.23 lM for memantine). By taking into account the therapeutic concentrations of these drugs attained in the human brain [60] , it was determined that amantadine acted at both the r and PCP binding site, while memantine only acted at the PCP binding site. Receptor occupancy studies have been performed for several classes of drugs by means of PET scans, and clinical data are available for dopamine D1 and D2 receptors (antipsychotics [61] [62] [63] ), histamine H1 receptors (antidepressants [64] ) and serotonin 5-HT2 receptors (antipsychotics [63] [70] . HIV also causes a spectrum of neurocognitive deficits in patients, and, in such instances, neurocognitive test scores, such as the Global Deficit Score (GDS) have been developed as a PD measure to provide a baseline of neurocognitive impairment and to track disease progression [71] .
The following three sections examine currently available target site clinical pharmacology data for three disease states: psychosis/schizophrenia, Alzheimer's disease and neuro-HIV. The reader is referred to Table 2 for more detailed information on the studies that are referenced in this article.
Clinical PK and PD of Antipsychotics in the CNS
Since chlorpromazine was approved over 60 years ago, there are now 21 FDA-approved first-and second-generation antipsychotics for the treatment of pediatric and adult psychosis. Despite significant advances in the field, a critical area that is yet to be fully addressed with these drugs is the variability in PD response required for efficacy, III. Neuro-HIV Pharmacokinetics and the relationship to target site exposure. There is also a lack of consensus on the appropriate PK target measure to correlate to antipsychotic efficacy. Antipsychotic drugs are known to penetrate readily into the brain. For example, haloperidol is found in the brain tissue at concentrations that are 10-to 30-fold higher than serum concentrations [72] . Further reports of brain tissue concentration of antipsychotics are available from autopsy tissue; a 2012 analysis in the prefrontal cortex tissue from 18 human autopsy samples noted high concentration of several drugs such as olanzapine (33,378 ng/g) and quetiapine (16,769 ng/g) [73] ; however, such reports often include no supporting information, such as plasma concentrations and postmortem interval of collection, and are therefore difficult to interpret. Given that olanzapine and the other drugs showed a range from undetectable (\2 ng/ g) to high concentrations, the authors postulated that the exceedingly high concentrations were the result of overdose. Therefore, such studies may not provide accurate information about the therapeutic range of concentrations ADAS-Cog Alzheimer's Disease Assessment Scale-cognitive subscale, MMSE Mini-Mental State Examination, IADL Instrumental Activities of Daily Living, CSF cerebrospinal fluid, PK pharmacokinetic, PD pharmacodynamic, PBPK physiologically-based pharmacokinetics, PET positron emission tomography, EC 50 50% effective concentration, AChE acetylcholinesterase, C max maximum concentration, T max time to reach C max , t elimination half-life, ARV antiretroviral, CPE CNS Penetration Effectiveness of antipsychotics. For the newer antipsychotics aripiprazole, lurasidone, and perospirone, clinical brain PK are unknown [74] ; however, extensive tissue distribution is evidenced by their large apparent volume of distribution of 400-6000 L [74] . In the absence of brain tissue concentration data, CSF concentration may be predictive of unbound brain tissue PK [27] , although this has not been verified in humans. Antipsychotics extensively enter the CSF [31] and historical estimates of total CSF:plasma protein-unbound concentration ratios for the older agents are indicative of significant binding to CSF proteins. For example, from a study of thioridazine in 48 patients, lumbar puncture followed by venipuncture was performed to obtain ratios of parent drug and metabolite in CSF compared with plasma. The average total CSF:unbound plasma ratio of thioridazine was determined to be 6 and ranged from 1.9 to 16.9 [75] , although it is unknown if all patients in this analysis were under steady-state conditions or what the time of sampling of CSF and plasma was relative to the dose [75] . From the same analysis, mean free fraction of thioridazine in the CSF was 49% and the unbound concentration in CSF was twice that in plasma, possibly on account of passive diffusion of thioridazine across the BBB. A significant correlation (p = 0.002) was shown between the unbound concentration of thioridazine in plasma and CSF [75] , suggesting that unbound concentrations in plasma could potentially be used as a surrogate for CSF concentrations or neuroleptic efficacy. In a later study, the plasma from 53 patients newly started on thioridazine 200 mg/day was sampled 12 h postdose six times over the course of 2 weeks; however, this analysis did not establish any link between plasma concentrations of thioridazine and antipsychotic efficacy [76] . Substrates of drug efflux transporters (e.g. risperidone and P-gp affinity), may show a lack of correlation between plasma and CSF concentrations. In these cases, other correlates of efficacy such as unbound CSF drug concentrations need to be used. More recent PK/PD analyses have explored the relationship between CSF concentration of antipsychotics and receptor occupancy data [77, 78] . In general, while CSF concentrations of antipsychotics correlated with efficacy (e.g. chlorpromazine) [79, 80] , this is not always the case due to difficulties in quantifying low CSF drug concentrations (e.g. haloperidol) [79, 81] . Another potential confounder in the relationship between drug concentration and efficacy occurs if there is metabolism to a moiety with antipsychotic effect. For example, the active metabolite of risperidone, 9-hydroxyrisperidone (paliperidone), is itself a marketed antipsychotic.
The importance of combined PK/PD modeling compared with PD alone has been demonstrated for antipsychotics. Aripiprazole was administered in 18 subjects, from 2 to 30 mg, and PET scans were taken predose and 3, 4, 5, and 120 h postdose [82] . Hysteresis was present in the relationship between dopamine receptor occupancy and plasma concentrations due to delayed effect-site equilibration. This resulted in the 50% effective concentration (EC 50 ) value changing, based on the type of modeling performed. With the combined PK/PD analysis of predicted effect-site concentration versus receptor occupancy, the EC 50 was 8.6 ng/mL [82] ; however, considering only PD, the EC 50 was slightly higher (11.1 ng/mL) due to hysteresis causing a change in the concentration-response slope. Therefore, for drugs where there is discrepancy between the time course of measured plasma concentration and receptor occupancy [82, 83] , a combined PK/PD analysis results in more reliable estimates of activity and accurate PD endpoints.
Clinical PK and PD of Drugs Used to Treat
Alzheimer's Disease in the CNS
In the months of September-November of 2017, interpedine and verubecestat were the latest drug failures for Alzheimer's disease [84] . An examination of the clinical pharmacology of the currently approved drugs for Alzheimer's identifies several potential sources for failure of clinical trials. Alzheimer's is a progressive disease where deteriorating brain pathology may lead to altered drug concentrations in the brain. This may be challenging when interpreting PK results from healthy volunteers or animal models. For example, a recent PET scan analysis performed 2.5-3 h (time to reach maximium concentration [T max ]) after a single oral dose of 1 mg or 30 lg 11 Cdonepezil in four healthy women [85] showed that the mean standardized unit value for mean intensity of pixels imaged (SUV mean ) was 0.9 in the brain for both doses, which is indicative of an almost even distribution of radioactivity in the brain compared with the rest of the body. However, in a study of donepezil in patients with Alzheimer's disease, despite achieving concentrations in the CSF that were tenfold lower than plasma, higher concentrations at 24 h postdose compared with 12 h postdose were observed in CSF but not plasma [86, 87] . This is thought to be due to the degradation of P-gp protein in the progressive pathogenesis of Alzheimer's disease (donepezil is a substrate of P-gp) that reduces the efflux of drug from CSF [87] . Given the localization of P-gp in the BBB and its role in the efflux of drugs from the brain tissue, one might expect similar accumulation of donepezil to also occur in brain tissue of Alzheimer's patients, however this is unknown. Another consideration is the suitability of surrogate PK measurements and their relationship with target site concentrations. For the NMDA receptor antagonist memantine, concentrations in the CSF from six patients (0.05-0.3 lM) were 50% lower than serum concentrations [88] , while the brain tissue concentration of memantine measured from a single autopsy patient (5.7 mg/kg) was 2.7-fold higher than the heart blood concentration (2.1 lg/ml), and 6.9-fold higher than the femoral blood concentration (0.83 lg/ml) [89] . While such data may be too sparse to interpret, memantine is a basic compound (pKa = 10.7) [88] , and sequestering within acidic lysosomes via pH partitioning and lysosomal trapping may be responsible for the enhanced brain accumulation of the drug compared with CSF. While clinical brain tissue concentrations are unknown for the acetylcholinesterase (AChE) inhibitor rivastigmine [90] , continuous CSF sampling in 18 patients at steady state for up to 12 h postdose [91] demonstrated that rivastigmine exhibited differential PK in plasma and CSF. The maximum concentration (C max ) in CSF was lower than plasma by two-to four-fold, and T max in CSF was longer than plasma (1.4-3.8 h compared with 0.5-1.67 h).
Limited data are available on the utility of PD measures in patients with Alzheimer's disease. For example, an earlier review noted complications of using AChE activity measurements as an outcome measure due to confounding by a number of factors such as diet, concomitant medication, or time of lumbar puncture [92] , making the effect size of PK/ PD analyses more difficult to interpret. Furthermore, while some studies utilize plasma concentrations to correlate with treatment outcomes [93] , plasma concentrations must first be validated as an appropriate surrogate for the target site.
Clinical PK and PD of Antiretrovirals in the CNS
In 2007, research nosology in the field of HIV was updated [71] to provide guidance on the neurocognitive disorders caused due to HIV-collectively called HIV-associated neurocognitive disorders (HAND). Since this time, the CNS has been implicated as an anatomical reservoir for HIV [94] [95] [96] [97] , capable of harboring latent viral infection in macrophage and microglia cells in the brain. To advance our understanding of both the treatment and potential cure for HIV in the CNS, it is imperative to understand the PK of ARVs in the CNS and their relationship with neurocognition and latent reservoirs. ARV PK have been extensively studied in the CSF and the reader is referred to two reviews summarizing this topic [44, 98] . Using measures of CSF PK of ARVs, along with physicochemical properties of the drugs and clinical utility, Letendre devised a CNS Penetration Effectiveness (CPE) score that accounts for efficacy of ARVs and extent of penetration into the CNS [99] . The scores range from 1 to 4, with 1 being less effective (having the lowest CNS penetration) and 4 being most effective (having the highest CNS penetration) [99] . ARVs having a higher CPE score cause greater reduction in viral load in the CSF in HIV patients [100] ; however, the correlation between CPE score and degree of neurocognitive impairment in patients with HAND is variable. For example, while improvement in neurocognitive function was noted by using agents with a higher CPE score in some studies [101] , there are instances where a higher CPE was not associated with neurocognitive improvement [102] , or where a higher CPE was associated with poorer functioning [103, 104] .
Given the contradicting PK/PD results, one hypothesis is that brain tissue concentration of ARVs may be a better predictor of neurocognitive impairment in patients with HAND; however, there are sparse clinical data on the agreement between CSF and brain tissue concentrations of ARVs. In a small study by Bumpus and colleagues, subcompartmental brain tissue concentration of ARVs was evaluated in nine HIV-positive adults who had AIDS at the time of death [105] . Concentrations in white matter, cortical gray matter, and globus pallidus regions of the brain were taken from necropsy samples and compared with historical CSF concentration data [105] . No difference in brain and CSF concentration was found for efavirenz, emtricitabine, atazanavir and lamivudine; however, for tenofovir, the overall brain concentration of 206 ng/g was 37-fold higher than CSF. For lopinavir, a protease inhibitor, greater accumulation was found in white matter ([400 ng/g) compared with other brain regions (\25 ng/ g). Contrary to these data, a recent in silico model [59] predicted that efavirenz accumulates in brain tissue, with a median tissue to plasma penetration ratio of 15.8. Data recently published in 12 non-human primates [106] showed that tenofovir, emtricitabine, efavirenz, raltegravir, maraviroc, and atazanavir all reached higher total concentrations in brain tissue compared with CSF at trough. For efavirenz, the brain tissue to CSF concentration ratio was highest (769-fold), and the brain tissue to plasma penetration ratio ranged from 3 to 5.7, indicating accumulation of efavirenz. Since information on patient adherence was not available for the study by Bumpus et al., and comparisons between brain tissue and CSF concentrations were made with historical CSF estimates, low adherence to an ARV regimen before death could explain why efavirenz concentrations were equivalent to the CSF measurements and much lower in these samples than that demonstrated in the non-human primates or predicted in the model.
A critical area for future investigation is PK/PD correlations as they relate to the development of latent reservoirs in target cells of the brain tissue. With advances in MS imaging, this work may be able to determine specific distribution patterns of ARVs in the brain [20] that can lead to differential viral growth or establish latency if there is insufficient ARV coverage. Another area of research is to understand the optimal range of intracellular concentration that can prevent HIV cellular infection without CNS toxicity [107] .
7 Optimization of PK/PD
Study of Biomarkers
In Alzheimer's disease, abnormal aggregation of protein can manifest as cognitive impairment or dementia [108] . Often, protein accumulation processes begin before clinical manifestations. Therefore, the search for quantifiable proteins or biomarkers in the CSF or blood is important for diagnosis. Biomarkers may also have utility as PD endpoints, and a recent review identified amyloid and tau in the CSF as commonly used biomarker outcome measures in ongoing clinical trials for Alzheimer's disease [109] . As previously demonstrated [110] , the utility of these measures comes from the stability of these biomarkers over time and significant differences in concentrations attained between patients with Alzheimer's disease and healthy volunteers. Utility of biomarkers to aid in antidepressant drug development was recently demonstrated by Kielbasa and Lobo. In an indirect response analysis, plasma PK concentrations of the antidepressants atomoxetine, duloxetine and edivoxetine were modeled against the CSF concentration of 3,4-dihydroxyphenylglycol (DHPG) [111] , the deaminated form of norepinephrine, as a biomarker. The analysis showed that the antidepressants all had a maximal inhibition rate of formation of DHPG (I max ) of 33-37% in plasma, and that edivoxetine was most potent; however, when in CSF, I max was much greater for edivoxetine (75%) compared with atomoxetine (53%) and duloxetine (38%). Further investigation of such biomarkers in the clinic can assist in the discovery of novel drug candidates.
Identification of novel biomarkers may also be useful in the field of neuro-HIV as a surrogate measure for neurocognitive impairment [112] to avoid the possibility of confounding with subjective psychiatric tests. In this regard, neurofilament light chain (NFL) has shown promise as a biomarker relating to HAND, although there have been no clinical studies evaluating the correlation of ARV and biomarker concentrations in HIV patients. Similarly, biomarkers should also be explored as a surrogate for the establishment of latent HIV reservoir in the brain [113] .
Modeling and Simulation
Several modeling tools have been developed to predict drug disposition within brain. Both a top-down approach (population PK modeling) [78] and a bottom-up approach (physiologically-based PK [PBPK] modeling) [26, 77, 114, 115] have been used to predict the brain penetration of various drugs in humans using in vitro and animal data. Gaohua and colleagues recently developed an extensive PBPK model that incorporated four additional compartments of the brain [26] : brain blood, brain mass, and cranial and spinal CSF. The model was well-suited to describe anatomy and physiology of the brain, including passive and active transport mechanisms through the BBB. The model was validated with measured clinical concentrations and in vitro data for phenytoin and paracetamol, and was used to simulate various scenarios that mimicked transporter-mediated mechanisms and CSF turnover. A recently developed generic PBPK model that incorporated five CSF compartments, including the extravascular drainage from CSF as well as intracellular and extracellular brain compartments, was utilized to predict the human brain and CSF PK of nine diverse drugs, including antipsychotics and antidepressants [116] . Such efforts will greatly improve our understanding of CNS target site approximations in humans. Modeling techniques further benefit from incorporating both the PK profile and the concentration and effect of endogenous substances. For example [117] , a mechanistic monkey PK/PD model was developed using plasma and CSF concentrations from the cisterna magna of two novel b-secretase 1 (BACE-1) inhibitors with b-amyloid and secreted amyloid precursor protein biomarkers [117] . This model could predict in vivo inhibition of BACE-1 and the effect on amyloid precursor processing by the BACE-1 inhibitors using in vitro cellular inhibition and enzyme activities, as well as drug concentration data.
PK/PD Translation from Preclinical Models
Developing innovative animal models for CNS research could address issues in clinical PK/PD, such as the relationship between effect-site drug concentrations and novel biomarkers, as well as allow for the discovery of novel targets. Zebrafish models have been refined to study several neurobehavioral disorders such as depression, Parkinson's disease, and attention-deficit hyperactive disorder (ADHD) [118] . They offer the advantages of low cost and genetic manipulation over traditional laboratory species such as rodents, and show a high degree of genetic and physiologic homology to mammals [119] . Novel rodent models have also been explored for pediatric epilepsy [120] and CNS involvement in HIV infection [121] .
For current animal models, their clinical applicability must be carefully examined. For example, certain animals may lack receptors or drug targets available in humans. Animal models may also differ in expression or activity of drug metabolizing enzymes and transporters. Comprehensive work by Terasaki and colleagues in quantitative targeted absolute proteomics (QTAP) has quantified transporter protein concentrations on the BBB of several species, including humans [50, 122] and found interspecies differences in several important transporters. For instance, humans have a greater absolute concentration (fmol/lg of protein) of BCRP compared with mice, while mice have a greater absolute concentration of P-gp, organic anion transporting polypeptide 1A2 (OATP1A2), MRP4, and OAT3. Similarly, absolute transporter concentrations in cynomolgus monkeys track more closely with humans than mice. Since multiple transporters contribute to both the uptake and efflux of drugs at the BBB, the relationship between transporter expression/activity and PK is not straight forward in the CNS. Therefore, while transporter differences at the BBB are not currently considered in allometry, models that account for differential transporter activity between species in the CNS are needed to understand if this warrants changes in the human dose.
Conclusions
Understanding drug penetration and effect at the various sites of the CNS is essential for neuroactive drug development. Currently, information on brain and CSF drug distribution exists for antipsychotics, Alzheimer's drugs and antiinfectives; however, the interaction between drug concentration and effect is still not clearly defined across these areas. Integrating PK/PD information for drugs acting in the CNS would allow for better prediction of first-in-human dose and improve the attrition rate of CNS drug research. In support of this, better utilization of tools such as biomarker identification and modeling can help pave the way for a more rigorous explanation of clinical brain PK/PD.
